Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 - Wikidata - awgldk - TriplyDB

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

http://www.wikidata.org/entity/Q35633680

about

Risk factors for triple-negative breast cancer in women under the age of 45 years Current approaches in treatment of triple-negative breast cancer Conditional independence relations among biological markers may improve clinical decision as in the case of triple negative breast cancers.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis.Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.Triple-negative breast cancer: role of specific chemotherapy agents Testing for HER2 in Breast Cancer: A Continuing Evolution.Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival Standard of care and promising new agents for triple negative metastatic breast cancer Race and the prognostic influence of p53 in women with breast cancer.Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer.Triple-negative breast cancers: an updated review on treatment options Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer Triple-Negative Breast Cancer: Clinical and Histological Correlations.Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.Triple negative breast cancer: unmet medical needs.Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy Triple-negative breast cancer: adjuvant therapeutic options.Triple negative breast cancer - our experience and review Enhanced cytotoxicity in triple-negative and estrogen receptor‑positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel.Which imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer?Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients.Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin.Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.Triple-negative breast cancer--current status and future directions.Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.Beyond triple-negative breast cancer: the need to define new subtypes.

P2860

Q24644075-54BD1A67-3BA3-42AD-BDA8-A9D041F4921F Q26801549-D572C15C-6579-4919-BC37-7FA498ABB10D Q33510468-8177E44A-FE84-4CF1-B1DE-13C91A680E52 Q33573055-BA845E35-693D-48EE-AE3F-BE744B76A313 Q33575459-6D36B98F-A44B-422E-A6ED-CC3858DB957B Q33715354-3119B607-B875-4FA6-ACB0-31A1F3CF669D Q33751806-947E858D-0F0A-4229-AE80-C46FD9D83D85 Q33780945-00BEA3E0-42BA-40BC-8691-5C1877FD6FE1 Q33858930-862531A4-B1C4-4A87-8160-C9DBCD9EA212 Q33900930-427AA3D3-2CC9-435A-832B-91E6301C151C Q34424285-48C1127A-C7EE-49FC-B86C-E5F4064DB05A Q34703865-45329240-784C-414F-9AF6-3970851E2A3B Q34774884-A915B885-EA38-4607-B398-642DC0BA512E Q34796332-7876E40D-F3DF-41C5-AD3B-484AD37AD88B Q35064200-EDEF7143-8197-4866-AD48-1299AD48CCC4 Q35145678-C18B4F6E-9DEB-4CE0-BF16-3121962CA1EE Q35167769-73498B54-7DAD-4A11-AD43-75D018FB89E5 Q35576252-55BBC7C1-F1A9-45AA-A0B5-7D570CE0E775 Q35584058-F826B430-B83B-417D-941F-5A2EA262C5DC Q35630269-A3EA546B-8973-4944-91AE-F9838E8A6B9F Q35654022-E8B3CC50-7521-4580-A62B-761773143214 Q35692146-79984EFB-CEEC-4BA5-83C6-0A83CD443560 Q36024205-710D4AFA-891D-4F98-AEB4-182D4EC11940 Q36528114-C2CA4700-3C0E-458E-BA31-693A46B9B98D Q36640972-199575CB-3A0B-45D0-9887-D0E7DC72490C Q36643018-08C9AD3A-77C0-45E4-82F7-830708B40EA8 Q36718459-B094CCD2-4B8F-4702-AE8C-2D5195D2837B Q36726996-CF5952B2-89C5-4559-B6C6-89033578D11A Q36794927-19CB320B-ABE3-404E-A17D-89940CBCF12E Q36825817-F5F7F3DA-DD40-4A3F-90C0-AA875F5AE963 Q36874902-20F97584-BABF-4DBF-91F7-F532F2CD663E Q36994508-88E47EB3-A2A1-4EDE-8955-4483B14B3941 Q37146751-CE05152A-BBFA-4802-B911-25E91DE6EE7A Q37277141-532AA118-1506-4A14-8282-B959607463C6 Q37290585-E84BF724-7C46-4194-95B4-0338CDEC3403 Q37374212-A73A991C-A18D-435D-AD4D-4ED914892BF5 Q37477489-7A910908-15FF-453B-9D7F-95E879CC31DC Q37630082-B1E34454-D171-4AC1-A29C-17FE31187A99 Q37687380-127E6436-939E-4103-B961-B82431CB64CF Q37782088-C82B89E5-CF60-4E42-9B77-D93D76607E06

P2860

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

http://www.wikidata.org/entity/Q35633680

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Molecular subtypes of breast c ...... sease: results from CALGB 9342

@ast

Molecular subtypes of breast c ...... sease: results from CALGB 9342

@en

type

label

Molecular subtypes of breast c ...... sease: results from CALGB 9342

@ast

Molecular subtypes of breast c ...... sease: results from CALGB 9342

@en

prefLabel

Molecular subtypes of breast c ...... sease: results from CALGB 9342

@ast

Molecular subtypes of breast c ...... sease: results from CALGB 9342

@en

P1433

Q35633680-062B3939-0F5D-4EE8-B6D5-3A28988B38A7

P1476

Q35633680-E2E40C07-4041-4978-ABF6-F4563072AB04

P2093

Q35633680-04658C9B-5660-4FBF-ADB1-A0AA94DCD8CB

Q35633680-0A3AA6EE-60F4-45BE-8B90-E810178ABBCE

Q35633680-569BCD04-9D7F-4659-ADB1-84697AAE1873

Q35633680-5EBFABB5-556D-498E-B627-49B55C1025F5

Q35633680-7BA5E94C-035D-4BBD-B119-0645FE754CA3

Q35633680-873C9D7B-51A9-4AD6-8F83-21BA233B2771

Q35633680-882C3425-DF1B-432B-8898-CE43B5AE16D7

Q35633680-9258C887-7824-4DA9-A3AD-5913C3E8C320

Q35633680-97C09CC7-D74A-4FB2-BB39-FD400093D177

Q35633680-9A596C1A-A28C-49C5-95C9-05ABAA6D8BBA

P2860

Q35633680-1CA309D6-F99B-4D3A-A618-5D7A5ECACF18

Q35633680-207EE471-206D-429A-84E3-C123F591810B

Q35633680-2B0249F3-C48B-49BF-8786-303917C2F400

Q35633680-2EC73023-28D5-463A-863E-D58E9541849F

Q35633680-2F23821E-219E-43F2-91EF-5E97AAE7F416

Q35633680-37D85666-45FB-4414-BF0C-85AF1AD2B7F3

Q35633680-3E2E8C87-7308-4916-A81C-D74D8DB1D21D

Q35633680-4205425D-D0A6-4A48-B8D8-D08C0DC45E09

Q35633680-48FCCE9D-D1A0-4E12-9D05-B203139AE6C5

Q35633680-49C6744F-B236-4897-B3CA-E42DB31E0A34

P2888

Q35633680-6D2D62C3-409B-4038-B71C-30D7DF0D24FD

P304

Q35633680-C40DC97D-83EF-42C2-B3D9-E333E1A4C10E

P31

Q35633680-C96BE21F-9264-4125-94E1-D415915EA798

P356

Q35633680-A3B91DD6-0285-42B8-948F-E88A1207F0D1

P433

Q35633680-95DFEE03-596F-419F-AF75-B00F8B3FADE2

P478

Q35633680-4F020F26-7CE3-4BCD-A255-AB630C9A03D3

P50

Q35633680-565427C0-1D4B-42F0-A474-37DE0E280F4E

P577

Q35633680-DC969820-1D11-4B06-AF6D-5DF9036BAD62

P5875

Q35633680-FC7BB325-C2DC-4AD9-BC94-926F56524FD9

P6179

Q35633680-02858955-59B2-4204-AE09-98B36D970038

P698

Q35633680-1F0EFD1E-DE5F-4308-9883-31DBBFC39592

P932

Q35633680-2EE76978-DE13-4255-942B-BC9E8470EAB6

P356

P1433

Breast Cancer Research

P1476

Molecular subtypes of breast c ...... sease: results from CALGB 9342

@en

P2093

Alexander Miron

http://www.w3.org/2001/XMLSchema#string

Daniel F Hayes

http://www.w3.org/2001/XMLSchema#string

David Cowan

http://www.w3.org/2001/XMLSchema#string

Donald Berry

http://www.w3.org/2001/XMLSchema#string

Eric P Winer

http://www.w3.org/2001/XMLSchema#string

Ira Bleiweiss

http://www.w3.org/2001/XMLSchema#string

Jonathan Lara

http://www.w3.org/2001/XMLSchema#string

Lyndsay N Harris

http://www.w3.org/2001/XMLSchema#string

Lynn Dressler

http://www.w3.org/2001/XMLSchema#string

Matthew Ellis

http://www.w3.org/2001/XMLSchema#string

P2860

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Gene expression profiling predicts clinical outcome of breast cancer

Molecular portraits of human breast tumours

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

Cancer statistics, 2004

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

Predicting the clinical status of human breast cancer by using gene expression profiles.

An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.

P2888

P304

R66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR1622

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Gloria Broadwater

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6669840

http://www.w3.org/2001/XMLSchema#string

P6179

1047987206

http://www.w3.org/2001/XMLSchema#string

P698

17129383

http://www.w3.org/2001/XMLSchema#string

P932

1797029

http://www.w3.org/2001/XMLSchema#string